Concepedia

Author

Anke Schulz

Bayer (Germany)

Also Known As

Anke Schulz, Elizabeth Fox

26

Publications

321

Citations

8

H-Index

21

Concepts

All Affiliations

Bayer (Germany)University of Colorado DenverUniversity of Colorado Cancer CenterBayer (United States)Antwerp University Hospital
AS

About

Anke Schulz is an author at Bayer (Germany) specializing in medicine, pathology, and molecular oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

92

2

Pathology

3

3

92

3

Pharmacology

2

2

72

4

Public Health

1

1

20

5

Obstetrics

1

1

20

Anke Schulz

×

7

Publications

282

Citations

7

H-Index

YearCitations

AKT1 E17K mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection

Marion Rudolph, Tobias Anzeneder, Anke Schulz,

BMC Cancer

2016

81

Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer

Jean‐Luc Van Laethem, Hanno Riess, Jacek Jassem,

Targeted Oncology

2016

60

Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VeRT Trial

Paulus Kirchhof, Michael D. Ezekowitz, Yanish Purmah,

TH Open

2020

53

Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study

Alessandro D. Santin, Ignace Vergote, Antonio González-Martı́n,

International Journal of Gynecological Cancer

2022

36

Cytokeratin-19 as a biomarker in urine and in serum for the diagnosis of endometriosis – a prospective study

Lorenz Kuessel, Agnes Jaeger-Lansky, Petra Pateisky,

Gynecological Endocrinology

2013

20

Left atrial thrombus resolution in non-valvular atrial fibrillation or flutter: biomarker substudy results from a prospective study with rivaroxaban (X-TRA)

Kazuo Miyazawa, Daniele Pastori, Christoph Hammerstingl,

Annals of Medicine

2018

20

Phase II study of refametinib (BAY 86-9766), an allosteric dual MEK 1/2 inhibitor, and gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer.

Jean‐Luc Van Laethem, Jacek Jassem, Volker Heinemann,

Journal of Clinical Oncology

2014

12

Page 1